市場調查報告書

細胞化驗的全球市場:各產品、技術、應用、終端用戶、地區成長率,趨勢及預測(2018年∼2023年)

Cell-Based Assay Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 390837
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
細胞化驗的全球市場:各產品、技術、應用、終端用戶、地區成長率,趨勢及預測(2018年∼2023年) Cell-Based Assay Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球細胞化驗市場,預計從2018年到2023年的預測期間內以8.2%的年複合成長率成長。細胞化驗,是醫療保健中多種目的的研究實驗室工具,為了決定藥物的功能性及有效性,使用抗體或其他部分以特定的細胞為標的進行設計。 R&D的支出增加,政府所實行的措施的強化,技術創新的發展等,成為北美支配該市場的幫助。

本報告提供全球細胞化驗市場調查,整體市場趨勢,各產品、技術、應用、終端用戶、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等資訊總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 成長要素
    • 慢性疾病及文明病的流行
    • 發現新藥的研究開發的投資增加
    • 細胞基礎的方法論的技術進步的高漲
    • 高通量篩檢法的採用的增加
  • 阻礙因素
    • 高維修運用與成本
    • 運用這些技術的熟練者不足
    • 嚴密的控制途徑
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品
    • 細胞株
    • 試劑及套件
    • 金屬板
    • 其他的消耗品
  • 各技術
    • 自動處理
    • 流式細胞技術
    • 免標定檢測
    • 高通量篩檢
    • 其他
  • 各應用領域
    • 藥物研發
    • ADME研究
    • 其他應用
  • 終端用戶
    • 學術機構
    • 製藥及生物科技企業
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Corning, Inc.
  • Danaher Corporation
  • DiscoverX Corporation
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Perkin Elmer, Inc.
  • Promega Corporation
  • Thermo Fisher Scientific, Inc.
  • 其他

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 52690

The cell-based assay market will show rapid growth due to the rising prevalence of chronic diseases and lifestyle disorders, increasing investments in R&D for drug discovery and the rise in technological advancements in cell-based methodologies.

The rising prevalence of chronic diseases and lifestyle disorders, such as cancer, cardiovascular, diabetes, and neurological disorders is one of the primary factors fueling the market growth. According to the WHO, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. It has been calculated that, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of NCDs is expected to increase to 57% by 2020.

Almost half of the total chronic disease deaths are attributable to cardiovascular diseases, obesity and diabetes are also showing increasing trends. Thus, the rise in chronic diseases leads to demand growth for cell-based assays for new drug discoveries, making it a vital factor for market growth. In addition, the demand for cell-based assay has increased significantly owing to a surge in cell-based applications in drug discovery and the rise in technological advancements in cell-based assays methodologies.

Key Market Trends

Drug Discovery is Expected to be the Largest Growing Segment Under Application in the Cell-Based Assay Market

The drug discovery segment is anticipated to show high growth in the market and this growth can be attributed to the increase in the R&D investment by biopharmaceutical companies. In addition, the rise in the prevalence of chronic diseases, such as cancer, osteoarthritis, cardiovascular diseases, and diabetes, is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market. In cell-based assays, functional cells are used as diagnostic tools in research for new drugs that help in drug discovery.

North America is Found Leading the Cell-Based Assay Market

North America is the leading region across the world in terms of market share owing to the well-established healthcare sector along with the high adoption of cell-based therapies. In the United States, the prevalence of chronic diseases, such as cancer, osteoarthritis, and diabetes, is increasing that is fueling the demand for cell-based assays for newer drug discoveries, making it a vital factor for the growth of this market.

Asia Pacific is expected to register the highest CAGR in the market during the forecast period. Growth in the APAC region is largely driven by the increasing R&D investment by the government and increasing infrastructural development in the region.

Competitive Landscape

The key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., and Promega Corporation. Product innovation and ongoing R&D activities to develop advanced technologies have helped in boosting the growth of the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Diseases and Lifestyle Disorders
    • 4.2.2 Increasing Investments in R&D for Drug Discovery
    • 4.2.3 Rise in Technological Advancements in Cell-based Methodologies
  • 4.3 Market Restraints
    • 4.3.1 High Maintenance and Operational Costs
    • 4.3.2 Lack of Skilled Personnel to Operate these Technologies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Cell Lines
      • 5.1.1.1 Primary Cell Lines
      • 5.1.1.2 Stem Cell Lines
      • 5.1.1.3 Others
    • 5.1.2 Reagents and Kits
    • 5.1.3 Microplates
    • 5.1.4 Other Consumables
  • 5.2 By Technology
    • 5.2.1 Automated Handling
    • 5.2.2 Flow Cytometry
    • 5.2.3 Label-free Detection
    • 5.2.4 High-throughput Screening
    • 5.2.5 Others
  • 5.3 By Application
    • 5.3.1 Drug Discovery
    • 5.3.2 Other Applications
  • 5.4 By End-user
    • 5.4.1 Academic & Government Institutes
    • 5.4.2 Pharmaceutical and Biotechnology Companies
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Bio-Rad Laboratories, Inc.
    • 6.1.3 Corning Inc.
    • 6.1.4 Danaher Corporation
    • 6.1.5 Thermo Fisher Scientific Inc.
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Merck KGaA
    • 6.1.8 Perkin Elmer Inc.
    • 6.1.9 Promega Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS